Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dwaine Rieves

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Chest|August 13, 2002
Suffer the childrenDwaine Rieves
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 13, 2022
What Does an Imaging "Selection" Claim Actually Mean?Rafel Dwaine Rieves
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 23, 2016
The Use of Published Clinical Study Reports to Support U.S. Food and Drug Administration Approval of Imaging AgentsDwaine Rieves, Paula Jacobs
The New England Journal of Medicine|August 31, 2012
Brain amyloid imaging--FDA approval of florbetapir F18 injectionLucie Yang, Dwaine Rieves, Charles Ganley
The New England Journal of Medicine|November 30, 2006
Judging the safety of aprotininR Dwaine Rieves, Karen D Weiss
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2013
Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticalsAlexander Gorovets, Louis Marzella, Dwaine Rieves, et al.
The New England Journal of Medicine|November 25, 2006
Judging the safety of aprotininDennis T Mangano, R Dwaine Rieves, Karen D Weiss
American Journal of Hematology|March 5, 2010
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney diseaseMin Lu, Martin H Cohen, Dwaine Rieves, et al.
Oncology (Williston Park, N.Y.)|January 2, 2010
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraAndrew Dmytrijuk, Kathy Robie-Suh, Dwaine Rieves, et al.
Radiology|August 28, 2012
Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug AdministrationLucie Yang, Ira Krefting, Alex Gorovets, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Chest|August 13, 2002
Suffer the childrenDwaine Rieves
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 13, 2022
What Does an Imaging "Selection" Claim Actually Mean?Rafel Dwaine Rieves
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 23, 2016
The Use of Published Clinical Study Reports to Support U.S. Food and Drug Administration Approval of Imaging AgentsDwaine Rieves, Paula Jacobs
The New England Journal of Medicine|August 31, 2012
Brain amyloid imaging--FDA approval of florbetapir F18 injectionLucie Yang, Dwaine Rieves, Charles Ganley
The New England Journal of Medicine|November 30, 2006
Judging the safety of aprotininR Dwaine Rieves, Karen D Weiss
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2013
Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticalsAlexander Gorovets, Louis Marzella, Dwaine Rieves, et al.
The New England Journal of Medicine|November 25, 2006
Judging the safety of aprotininDennis T Mangano, R Dwaine Rieves, Karen D Weiss
American Journal of Hematology|March 5, 2010
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney diseaseMin Lu, Martin H Cohen, Dwaine Rieves, et al.
Oncology (Williston Park, N.Y.)|January 2, 2010
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraAndrew Dmytrijuk, Kathy Robie-Suh, Dwaine Rieves, et al.
Radiology|August 28, 2012
Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug AdministrationLucie Yang, Ira Krefting, Alex Gorovets, et al.
Pageof 2